After more than sixty years we are still unclear whether LSD has a place in clinical psychiatry
Arthur Saniotis
Research in Psychotherapy Psychopathology Process and Outcome October 1, 2020 DOI: 10.4081/ripppo.2020.464 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Letter to the editor Peer reviewed |
|---|---|
| Intervention | Lysergic Acid Diethylamide (LSD) |
| Topics | Addiction Anxiety LSD |
| Keywords | Depression economics Hallucinogen Terminal cancer Psychotherapist |
| Citations | 1 |
| Key points | LSD was historically used in psychotherapy for depression, anxiety related to terminal cancer, addiction, and pain, and its use is again under scientific debate. |
Abstract
Dear Editor, The use of the psychedelic Lysergic Acid Diethylamide (LSD) has again provoked scientific debate over its efficacy and safety. In the 1950s-1960s LSD was used in psychotherapy for treating depression, anxiety related to terminal cancer, addiction, and pain. (...)
Citations in the library
Cites 9
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology April 26, 2017
- The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology July 19, 2010
- LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects Journal of Psychopharmacology November 11, 2014
- 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry May 1, 2018
and 4 more in the library